|

A Post-marketing Observational Study of Tasfygo in Participants With Unresectable Biliary Tract Cancer With Fibroblast Growth Factor Receptor 2 (FGFR2) Fusion Gene Positivity Who Progressed After Chemotherapy

RECRUITINGSponsored by Eisai Co., Ltd.
Actively Recruiting
SponsorEisai Co., Ltd.
Started2025-07-10
Est. completion2032-11-20
Eligibility
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06793709

Summary

The primary purpose of this study is to investigate the safety of Tasfygo.

Eligibility

Healthy volunteers accepted
Inclusion Criteria:

1\. Participants with unresectable biliary tract cancer with FGFR2 fusion gene positivity who are naïve to Tasfygo tablet and progressed after chemotherapy.

Exclusion Criteria:

Not applicable.

Conditions2

Biliary Tract CancerCancer

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.